Reagents News and Research

RSS

Researchers develop new method for sequencing single cells in an efficient manner

RNA sequencing is a powerful technology for studying cells and diseases. In particular, single-cell RNA sequencing helps uncover the heterogeneity and diversity of our body.

1 Jun 2021

New discovery in Ewing sarcoma may prevent tumor metastasis from occurring

A new discovery in Ewing sarcoma, an aggressive and often fatal childhood cancer, has uncovered the potential to prevent cancer cells from spreading beyond their primary tumor site.

1 Jun 2021

Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology

Aptamer Group today announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda.

From Aptamer Group 28 May 2021

Rapid Novor First to Decode Polyclonal Antibodies Using Only Proteomics

Novel antibody discovery platform REpAb® unlocks direct access to key antibodies through next-generation protein sequencing

From Rapid Novor Inc 27 May 2021

Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases

Waters Corporation today introduced a new RUO LC-MS test method to advance critical infectious disease research.

From Waters Corporation 27 May 2021

CASdetec: new CRISPR-based SARS-CoV-2 detection platform detects nucleic acids with high sensitivity and specificity

To add to existing CRISPR-based nucleic acid detection protocols, a team of researchers recently established a new SARS-CoV-2 detection protocol based on their previously reported platform - CDetection (Cas12b-mediated DNA detection). They combined nucleic-acid amplification methods and sample treatment protocols with CDetection and established an integrated nucleic acid detection platform called CRISPR-assisted detection or CASdetec. CASdetec has a detection limit of 1×104 copies/mL for SARS-CoV-2 pseudovirus, without any observed cross-reactivity.

26 May 2021

Researchers develop a method to detect SARS-CoV-2 and variants simultaneously

Researchers demonstrate a method of detecting the presence and mutations in the SARS-CoV-2 virus using the smaller and cheaper Oxford Nanopore sequencer, a method they believe could make pandemic surveillance faster and cheaper.

26 May 2021

New testing protocol for SARS-CoV-2 can process thousands of samples within 48 hours

Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.

25 May 2021

Biorbyt receives Queen’s Award for Enterprise

Biorbyt is delighted to have been honoured with a Queen’s Award for Enterprise for its outstanding achievements in international trade.

From Biorbyt 24 May 2021

Researchers validate new COVID-19 test kit that could spur the expansion of more rapid testing

Simon Fraser University researchers have validated a faster, cheaper COVID-19 test that could kickstart the expansion of more widespread rapid testing. Study results have been published in The Journal of Molecular Diagnostics.

22 May 2021

New study will help investigate innate immune responses to viral infections

Researchers from Boston University School of Medicine (BUSM) report the formation of human cells containing a green fluorescent protein or GFP (one of the most important proteins in biology and fluorescence imaging) genetically fused with two interferon stimulated genes (ISGs), namely Viperin and ISG15.

19 May 2021

New COVID-19 testing technology is a cheaper, faster alternative to tube-based RT-PCR tests

Throughout the COVID-19 pandemic, supply chain shortages of reagents and test kits have limited the rapid expansion of clinical testing needed to contain the virus.

18 May 2021

New coronavirus test can get fast, accurate results from saliva samples

A new coronavirus test can get accurate results from a saliva sample in less than 30 minutes, researchers report in the journal Nature Communications.

18 May 2021

ACROBiosystems makes donations to BEI Resources, accelerating the process of attacking SARS-CoV-2 variants globally

Multiple SARS-CoV-2 variants are emerging and circulating globally; the battle against COVID-19 pandemic is still challenging. Recently, ACROBiosystems donated SARS-CoV-2 mutant proteins to BEI Resources, a NIAID funded bioresource program, joining in the collective effort in attacking SARS-CoV-2 variants globally.

From ACROBiosystems 17 May 2021

A magnetofluidic platform for SARS-CoV-2 variant and respiratory pathogen detection

Recent research published on the medRxiv* server has developed a portable, magnetofluidic cartridge platform, for automated PCR testing in <30 min, for rapid multiplexed screening of pathogens. A multidisciplinary team of researchers at Johns Hopkins University and the Johns Hopkins University School of Medicine developed these cartridges for multiplexed detection of SARS-CoV-2 with distinctive variant mutations or with Influenza A and B.

13 May 2021

BioEcho receives CE-IVD mark approval for SARS-CoV-2 RNA extraction kit

BioEcho Life Sciences announces that the company has recently received CE-mark approval for their EchoLUTION Viral RNA/DNA Swab Kit product line.

11 May 2021

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.

10 May 2021

Rapid and sensitive SARS-CoV-2 detection from saliva using CRISPR

In a paper recently uploaded to the preprint server medRxiv by Edward Málaga Trillo et al. (April 29th, 2021), these methods are tested in combination with CRISPR-Cas detection in the field, demonstrating a sensitivity and specificity of 93.8% and 99%, respectively.

4 May 2021

New collaboration to study early detection of developmental differences in children

The University of Washington's School of Medicine Brotman Baty Institute for Precision Medicine is collaborating with Illumina, Inc. and GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, to study early detection of developmental differences in children.

29 Apr 2021

New COVID-19 testing strategy can quicken test results for healthcare workers

Fast turnaround of COVID-19 test results for healthcare workers is critical. Investigators have now developed a COVID-19 testing strategy that maximizes the proportion of negative results after a single round of testing, allowing prompt notification of results.

26 Apr 2021